Highlights 2009/10


Pipeline update

  • NVA237 (COPD) Novartis initiated Phase III studies in June 2009 triggering a $7.5m (£4.5m) milestone receipt. An extensive package of data is being compiled and Novartis expects to file for regulatory approval in 2011
  • VR315 (asthma/COPD)
    • EU Sandoz continues to make good progress
    • US Vectura continues development whilst further assessing FDA requirements
  • VR632 (asthma/COPD) Good progress continues with Sandoz on development for the European market
  • VR040 (Parkinson's disease) Phase II "at home" study on-going; results expected in 2010
  • VR496 (cystic fibrosis) Phase II proof-of-concept study on-going; results expected in early 2011
  • Expansion of pipeline Three new products under development: VR506 a generic inhaled corticosteroid for asthma expected to be ready for clinical studies later this year, and two specialty products VR461 and VR909 in pre-clinical development
  • Boehringer Ingelheim GmbH ("Boehringer Ingelheim") collaboration agreement concluded in November 2009

Post-year end

  • QVA149 (COPD) Novartis initiated Phase III studies in April 2010 triggering a $7.5m (£5.1m) milestone payment. Novartis expects to file for approval in 2012
  • VR315 US Receipt of $9.5m (£6.2m) from Sandoz in May 2010 in respect of the revised US agreement



Financial highlights